Beta Technologies


Quick Summary

Beta's eVTOL, Ava, combines the flight characteristics of a helicopter, drone and fixed-wing airplane with cockpit and control systems that revolutionize the pilot's interface. Beta has partnered with, and is funded by, United Therapeutics biotechnology company. The eVTOL is ultimately designed to carry organs from a manufacturing facility to hospitals.



Beta Technologies is based out of Burlington, Vermont, building and operating the Ava eVTOL.







Stage of Development

Preliminary Design


Prototype Build

Flight Testing

Certification

Commercially Operating
Technical Details

Company Name: Beta Technologies

Headquarters: Burlington, Vermont

Beta CEO: Kyle Clark

Product NameAva (prototype)

Type of Machine: Winged eVTOL Aircaft

Power: All-electric. Beta is also creating a recharging dock for the Ava – a landing pad that will recharge the aircraft.

Capacity: Ultimately designed for cargo - specifically, organ transport.

Wingspan: 34 feet

Vertical take-off and landing: 4 pairs of counter-rotating rotors. A flight controller distributes electric propulsion power based on position and direction of each rotor.

Fixed wing flight: rotors rotate forward (perpendicular to ground) and power consumption drastically decreases.

Range: 150 miles.

Speed: 170 mph.

Funding: Backed by biotechnology company, United Therapeutics.



Our Take on Beta


Beta Technologies is strategically located in Burlington, VT for easier access to the state's congressional delegation, the airport's leadership and, by extension, its Federal Aviation Administration staff - the company currently occupies a Horizon Air hangar at Burlington International Airport. While regulatory and certification hurdles are ahead for Beta's Ava, the relationships they have built will help them navigate that process. Beta has made over 170 test flights in 2018, and was able to go from an initial concept to "wheels off the ground" in just 10 months, an impressive feat.